RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Reduced-intensity conditioning with low dose ATG or alemtuzumab followed by allogeneic PBSC: A salvage therapy with an encouraging response rate and limited toxicity in relapsed/refractory multiple myeloma.
2002-01-01 Corradini, P; Milani, R; Ciceri, F; Montefusco, V; Peccatori, J; Mariotti, J; Olivieri, Attilio; Soligo, D; Gianni, Am; Perfetti, V; Bregni, M.
Reduced-intensity conditioning with thiotepa, fludarabine and melphalan for allogeneic transplantation in multiple myeloma
2006-01-01 Majolino, I; Carnevalli, E; Locasciulli, A; Di Bartolomeo, P; Scime, R; Corradini, P; Selleri, M; Narni, F; Musso, M; Bregni, M; Olivieri, Attilio; De Fabritiis, P; Pogliani, L; Ruscio, C; Bacigalupo, A.
Reduced-intensity conditioning with thiotepa, fludarabine and melphalan for allogeneic transplantation in multiple myeloma
2004-01-01 Majolino, I; Arana, Mg; Riccardi, M; Locasciulli, A; Bacigalupo, A; Di Bartolomeo, P; Scime, R; Olivieri, Attilio; Narni, F; De Fabritiis, P; Corradini, P.
Reduced-intensity conditioning with thiotepa, fludarabine and melphalan is an effective regimen for allogeneic transplantation in multiple myeloma
2005-01-01 Majolino, I; Arana, Mg; Riccardi, M; Locasciulli, A; Bacigalupo, A; Di Bartolomeo, P; Scime, R; Olivieri, Attilio; Narni, F; Bregni, M; De Fabritiis, P; Musso, M; Corradini, P.
Reduced-intensity thiotepa based conditioning and rabbit anti-thymocyte globulin for alternative donor transplants: a prospective GITMO trial
2005-01-01 Lamparelli, T; Fanin, R; Bandini, G; Raimondi, R; Faida, M; Scime, R; Bruno, B; Olivieri, Attilio; Alessandrino, Ap; Corradini, P; Ciceri, F; Di Bartolomeo, P; Sacchi, N; Pollicheni, S.
Reduction of the aplastic phase and hospitalization in patients receiving PBSC autotransplantation followed by erythropoietin plus filgrastim: A matched analysis of 79 consecutive procedures
2003-01-01 Olivieri, Attilio; Scortechini, I; Capelli, D; Montanari, M; Lucesole, M; Gini, G; Cecchi, S; Spitaleri, L; Troiani, E; Masia, Mc; Leoni, Pietro
Rituximab may allow to improve multi-organ involvement in patients with cGVHD.
2005-01-01 Zaja, Ff; Bacigalupo, A; Bosi, Aab; Scime, Rr; Milone, Gg; Falda, Mm; Vener, C; Laszlo, D; Alessandrino, Ep; Narni, F; Sica, S; Olivieri, Attilio; Sperotto, Aa; Fanin, Rr
Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: Results from a multicenter randomized GITMO trial.
2005-01-01 Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Am; Musso, M; Pulsoni, A; Olivieri, Attilio; Pavone, E; Pogliani, E; Scalabrini, Dr; Gallamini, A; Callea, V; Mantoan, B; Boccadoro, M; Majolino, I; Corradini, P; Gianni, Am; Tarella, C.
Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse
2014-01-01 Dodero, Anna; Spina, Francesco; Narni, Franco; Patriarca, Francesca; Benedetti, Fabio; Baronciani, Donatella; Rambaldi, Alessandro; Olivieri, Attilio; Dalto, Serena; Bruno, Benedetto; Vitolo, Umberto; Corradini, Paolo
Safety And Efficacy Of An Outpatient Dhap Schedule: An Experience On 101 Relapsed Lymphoma Patients
2013-01-01 Sampaolo, M; Olivieri, J; Gini, G; Bocci, C; Trappolini, S; Olivieri, Attilio; Leoni, Pietro
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Reduced-intensity conditioning with low dose ATG or alemtuzumab followed by allogeneic PBSC: A salvage therapy with an encouraging response rate and limited toxicity in relapsed/refractory multiple myeloma. | 1-gen-2002 | Corradini, P; Milani, R; Ciceri, F; Montefusco, V; Peccatori, J; Mariotti, J; Olivieri, Attilio; Soligo, D; Gianni, Am; Perfetti, V; Bregni, M. | |
| Reduced-intensity conditioning with thiotepa, fludarabine and melphalan for allogeneic transplantation in multiple myeloma | 1-gen-2006 | Majolino, I; Carnevalli, E; Locasciulli, A; Di Bartolomeo, P; Scime, R; Corradini, P; Selleri, M; Narni, F; Musso, M; Bregni, M; Olivieri, Attilio; De Fabritiis, P; Pogliani, L; Ruscio, C; Bacigalupo, A. | |
| Reduced-intensity conditioning with thiotepa, fludarabine and melphalan for allogeneic transplantation in multiple myeloma | 1-gen-2004 | Majolino, I; Arana, Mg; Riccardi, M; Locasciulli, A; Bacigalupo, A; Di Bartolomeo, P; Scime, R; Olivieri, Attilio; Narni, F; De Fabritiis, P; Corradini, P. | |
| Reduced-intensity conditioning with thiotepa, fludarabine and melphalan is an effective regimen for allogeneic transplantation in multiple myeloma | 1-gen-2005 | Majolino, I; Arana, Mg; Riccardi, M; Locasciulli, A; Bacigalupo, A; Di Bartolomeo, P; Scime, R; Olivieri, Attilio; Narni, F; Bregni, M; De Fabritiis, P; Musso, M; Corradini, P. | |
| Reduced-intensity thiotepa based conditioning and rabbit anti-thymocyte globulin for alternative donor transplants: a prospective GITMO trial | 1-gen-2005 | Lamparelli, T; Fanin, R; Bandini, G; Raimondi, R; Faida, M; Scime, R; Bruno, B; Olivieri, Attilio; Alessandrino, Ap; Corradini, P; Ciceri, F; Di Bartolomeo, P; Sacchi, N; Pollicheni, S. | |
| Reduction of the aplastic phase and hospitalization in patients receiving PBSC autotransplantation followed by erythropoietin plus filgrastim: A matched analysis of 79 consecutive procedures | 1-gen-2003 | Olivieri, Attilio; Scortechini, I; Capelli, D; Montanari, M; Lucesole, M; Gini, G; Cecchi, S; Spitaleri, L; Troiani, E; Masia, Mc; Leoni, Pietro | |
| Rituximab may allow to improve multi-organ involvement in patients with cGVHD. | 1-gen-2005 | Zaja, Ff; Bacigalupo, A; Bosi, Aab; Scime, Rr; Milone, Gg; Falda, Mm; Vener, C; Laszlo, D; Alessandrino, Ep; Narni, F; Sica, S; Olivieri, Attilio; Sperotto, Aa; Fanin, Rr | |
| Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: Results from a multicenter randomized GITMO trial. | 1-gen-2005 | Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Am; Musso, M; Pulsoni, A; Olivieri, Attilio; Pavone, E; Pogliani, E; Scalabrini, Dr; Gallamini, A; Callea, V; Mantoan, B; Boccadoro, M; Majolino, I; Corradini, P; Gianni, Am; Tarella, C. | |
| Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse | 1-gen-2014 | Dodero, Anna; Spina, Francesco; Narni, Franco; Patriarca, Francesca; Benedetti, Fabio; Baronciani, Donatella; Rambaldi, Alessandro; Olivieri, Attilio; Dalto, Serena; Bruno, Benedetto; Vitolo, Umberto; Corradini, Paolo | |
| Safety And Efficacy Of An Outpatient Dhap Schedule: An Experience On 101 Relapsed Lymphoma Patients | 1-gen-2013 | Sampaolo, M; Olivieri, J; Gini, G; Bocci, C; Trappolini, S; Olivieri, Attilio; Leoni, Pietro |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 158
- 1 Contributo su Rivista::1.5 Abst... 158
Data di pubblicazione
- 2020 - 2022 9
- 2010 - 2019 43
- 2002 - 2009 106
Rivista
- BONE MARROW TRANSPLANTATION 62
- BLOOD 52
- HAEMATOLOGICA 27
- HAEMATOLOGICA 8
- CLINICAL LYMPHOMA & MYELOMA 2
- ANNALS OF THE RHEUMATIC DISEASES 1
- BIOCHIMICA CLINICA 1
- BLOOD 1
- BONE MARROW TRANSPLANTATION 1
- HEMASPHERE 1
Lingua
- eng 23
Accesso al fulltext
- no fulltext 158